#USA #New York #Pomerantz LLP #Investor Alert #Omeros Corporation

Investor Alert: Pomerantz Law Firm Investigates Omeros Corporation

In a significant development for shareholders of Omeros Corporation, renowned Pomerantz LLP has initiated an investigation into potential securities fraud and improper business practices by the company and its executives. This comes in light of concerning announcements related to the company's marketing authorization application for its product, narsoplimab, which is intended for the treatment of thrombotic microangiopathy associated with hematopoietic stem cell transplants.

The investigation aims to determine whether the company has misled investors or violated any laws. On June 26, 2026, Omeros publicly disclosed a setback regarding its application, stating that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) had adopted a negative opinion regarding their request for marketing authorization. This news caused a noticeable decline in the company’s stock price, falling by 19.12%, highlighting investor concerns over the viability of narsoplimab.

Less than four months later, in mid-October 2026, the situation worsened as Omeros again faced negative feedback from the CHMP, which reiterated its earlier stance after reassessing the application. Following this announcement, the stock price dipped further by 13.78%, prompting further scrutiny and questions over the management response and communication strategy.

Pomerantz LLP is known for its strong commitment to protecting the rights of investors, having earned a reputation in the legal landscape as a premier firm specialized in class actions involving corporate fraud. Founded over 85 years ago by Abraham L. Pomerantz, the firm has consistently championed the causes of those affected by corporate misdeeds, securing substantial settlements in the process.

The ongoing scrutiny underscores the volatility and risks inherent within the pharmaceutical and biotech sectors, where regulatory hurdles and stakeholder communications can drastically influence market performance. If you are an investor in Omeros, Pomerantz encourages you to reach out to them for further information and to discuss potential participation in any future class action lawsuits against the company.

For those impacted by these events or interested in following developments, Omeros Corporation’s information channel remains open. Stakeholders can contact Danielle Peyton from Pomerantz at [email protected] or call her directly to explore options regarding their investments in light of the recent tumult.

As the firm proceeds with its investigation, the implications for Omeros Corporation will unfold, potentially leading to significant changes in stakeholder dynamics and investor confidence. Shareholders are advised to stay updated on further announcements and guidance from regulatory bodies that may affect Omeros's future.